Key facts
- This page summarizes Jesse Shefferman's Form 4 filing for Protara Therapeutics, Inc. (TARA).
- 7 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 01 Jul 2026, 16:10.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Sale
Gift
Gift
Gift
Gift
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Additional SEC filing notes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.03 to $4.14, inclusive. The reporting person undertakes to provide to TARA, any security holder of TARA, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Footnote F2
The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest, and this report should not be deemed an admission that the Reporting Person or any other person named herein is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Footnote F3
The reported securities held by the Samhold Family Trust were inadvertently included under the Reporting Person's direct holdings in the prior Form 4 filings filed by the Reporting Person on January 21, 2026, January 22, 2026 and January 27, 2026.
Footnote F4
25% of the shares underlying the option vested on January 19, 2025 and the remaining shares have vested or will vest in equal monthly installments thereafter over the following 36 months, subject to the Reporting Person's continuous service with the Issuer as of each such date.